ReviewMolecular biology reports2026
Unveiling the anti-cancer properties of apigenin via targeting different molecular signatures: A Review.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.Journal of enzyme inhibition and medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeApigenin, is a plant derived flavone found in parsley, celery and some spices. It has fascinated a lot of researchers because of its anti-viral, anti-bacterial, anti-inflammatory and above all its anti-cancer abilities. This review was created to understand the role of apigenin, in the prevention and treatment of cancer by targeting all hallmarks of cancer in in vitro and in vivo studies.
methodsVarious studies unfolding apigenin's role as anti-cancer agent were examined using databases like PubMed, Google scholar, Scopus and Science direct with an emphasis on its potential as an anti-proliferative, anti-apoptotic, and anti-migratory agent. Furthermore, studies that depicted epigenetic modulations and nano-based delivery were also scanned. Recent developments in nanoparticle-based delivery methods that increase apigenin's bioavailability and therapeutic effectiveness are also included.
resultsThe compiled evidence indicates that apigenin exhibits broad spectrum anticancer activity by modulating multiple cancer hallmarks, including apoptosis induction, autophagy regulation, suppression of metastasis, and inhibition of inflammatory and metabolic pathways such as GLUT1/GLUT2 mediated glucose uptake. Mechanistically, these effects are strongly linked to its epigenetic reprogramming ability, including regulation of HDACs, DNMT1, EZH2, and oncogenic miRNAs, leading to reactivation of tumor suppressor genes. Across in vitro and in vivo models, apigenin consistently demonstrates selective cytotoxicity toward cancer cells while sparing normal cells, largely through restoration of dysregulated signaling pathways. Additionally, it enhances chemosensitivity and overcomes multidrug resistance when used in combination with conventional chemotherapeutics. However, its therapeutic potential is partly limited by poor bioavailability, which is being effectively addressed through emerging nanoformulation strategies and computational (AI/bioinformatics) approaches for improved delivery and efficacy.
Indexed as
Identifiers
42189306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.